Ethnic and geographic variations in the incidence of pancreatitis and post-pancreatitis diabetes mellitus in New Zealand: a nationwide population-based study
Authors: Pendharkar SA et al.
Summary: This analysis of data from all district health boards in New Zealand investigated the incidence
of acute pancreatitis (AP), chronic pancreatitis (CP), and post-pancreatitis diabetes mellitus (DP) and the
effect of ethnic and geographic variations. The study period was from 1 January 2006 to 31 October
2015. On average, 2,072 new cases of AP, CP and DP were diagnosed in New Zealand every year. Crude
incidence rates (per 100,000 population per year) were 58.42 for AP, 3.97 for CP, and 7.95 for DP. Māori
had the highest incidence of AP (95.21 per 100,000 population per year), CP (6.27 per 100,000 population
per year), and DP (18.23 per 100,000 population per year). Across all age groups, the incidence of AP and
DP was at least 1.8 and 2.6 times higher in Māori than in New Zealand Europeans, and Pacific people were
more likely to develop DP than New Zealand Europeans in every age group, ranging from 1.90 times in
the 45–49 group to 6.86 in the ≥75 group. Auckland/Northland had the highest incidence of AP (135.25
per 100,000 population), and CP (9.03 per 100,000 population), while Lakes/Waikato had the highest
incidence of DP (20.64 per 100,000 population) in New Zealand.
Reference: Reference: N Z Med J. 2017;130(1450):55-68
Abstract
The contribution of Helicobacter pylori to excess gastric cancer in Indigenous and Pacific men: a birth cohort estimate
Authors: Teng AM et al.
Summary: This paper quantifies the contribution of Helicobacter pylori to excess gastric cancer among
Māori and Pacific men in New Zealand. The study researchers calculated age-standardised gastric cancer
rate ratios for 1981–2004 in Māori and Pacific men as well as European/Other men born between 1926
and 1940 (Cohort One) and between 1941 and 1955 (Cohort Two). Analyses comparing these rate ratios
with those restricted to H. pylori prevalent populations revealed that H. pylori contributed substantially to
excess gastric cancer incidence in Māori men (50% in Cohort One and 61% in Cohort Two) and Pacific
men (71% in Cohort One and 82% in Cohort Two).
Reference: Gastric Cancer. 2016 Nov 16. [Epub ahead of print]
Abstract
A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity
Authors: Teng AM et al.
Summary: These researchers developed a Markov macrosimulation model using life-tables and morbidity
data from a national burden of disease study, in order to evaluate cost-effectiveness of a H. pylori serologybased
screening programme in New Zealand in 2011 compared with current medical practice. The cost
of the screening programme was estimated at NZ$24,600 per quality-adjusted life year (QALY) gained
for the total population. The targeted screening program for Māori was more cost effective at $11,985
per QALY gained. Compared to current practice, the total net cost of a one-off total population H. pylori
screening programme for the 25–69-year age group was $293 million, with estimated health gains of
14,200 QALYs over the cohort’s lifetime, corresponding to a 17% reduction in the expected future gastric
cancer cases and deaths.
Reference: BMC Infect Dis. 2017;17(1):156
Abstract